- Home
- USB vs ALNY Comparison
USB vs ALNY Comparison
Compare USB & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USB
- ALNY
- Stock Information
- Founded
- USB 1863
- ALNY 2002
- Country
- USB United States
- ALNY United States
- Employees
- USB N/A
- ALNY N/A
- Industry
- USB Major Banks
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- USB Finance
- ALNY Health Care
- Exchange
- USB Nasdaq
- ALNY Nasdaq
- Market Cap
- USB 72.2B
- ALNY 59.6B
- IPO Year
- USB N/A
- ALNY 2004
- Fundamental
- Price
- USB $47.48
- ALNY $458.59
- Analyst Decision
- USB Buy
- ALNY Strong Buy
- Analyst Count
- USB 20
- ALNY 29
- Target Price
- USB $52.53
- ALNY $448.97
- AVG Volume (30 Days)
- USB 9.6M
- ALNY 1.0M
- Earning Date
- USB 10-16-2025
- ALNY 10-30-2025
- Dividend Yield
- USB 4.21%
- ALNY N/A
- EPS Growth
- USB 32.67
- ALNY N/A
- EPS
- USB 4.18
- ALNY N/A
- Revenue
- USB $25,560,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- USB $13.85
- ALNY $59.55
- Revenue Next Year
- USB $4.47
- ALNY $40.90
- P/E Ratio
- USB $11.36
- ALNY N/A
- Revenue Growth
- USB 1.81
- ALNY 5.01
- 52 Week Low
- USB $35.18
- ALNY $205.87
- 52 Week High
- USB $53.98
- ALNY $484.21
- Technical
- Relative Strength Index (RSI)
- USB 42.78
- ALNY 58.80
- Support Level
- USB $47.48
- ALNY $446.18
- Resistance Level
- USB $49.00
- ALNY $465.01
- Average True Range (ATR)
- USB 0.82
- ALNY 11.41
- MACD
- USB -0.32
- ALNY -2.05
- Stochastic Oscillator
- USB 0.49
- ALNY 65.04
About USB U.S. Bancorp
With assets of around $685 billion, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in Midwestern and Western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, and wealth services.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.